Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for XORTX Therapeutics Inc. (XRTX : NSDQ)

• Company Description    XORTX Therapeutics Inc. is a pharmaceutical therapeutics company. It focused on developing therapies to treat progressive kidney disease. XORTX Therapeutics Inc. is based in CALGARY, Alberta. Number of Employees: 17

• Price / Volume Information    Yesterday's Closing Price: $0.87 Daily Weekly Monthly 20 Day Moving Average: 221,097 shares Shares Outstanding: 3.79 (millions) Market Capitalization: $3.30 (millions) Beta: 0.51 52 Week High: $2.98 52 Week Low: $0.80 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -1.14% -4.84% 12 Week -8.23% -22.81% Year To Date -22.98% -27.87%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 3710 - 33RD STREET NW - ALBERTA,A1 T2L 2M1 CAN ph: 403-455-7727 fax: - adavidoff@xortx.com http://www.xortx.com

• General Corporate Information    Officers Allen Davidoff - Chief Executive Officer and President Anthony J. Giovinazzo - Non-Executive Chair Michael Bumby - Chief Financial Officer William Farley - Director Abigail Jenkins - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 98420Q306 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/13/25 Share - Related Items Shares Outstanding: 3.79 Most Recent Split Date: 11.00 (0.11:1) Beta: 0.51 Market Capitalization: $3.30 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/13/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.20 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 84.68% vs. Previous Quarter: -575.00% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/25 - - 03/31/25 - -36.38 12/31/24 - -124.23 ROA 06/30/25 - - 03/31/25 - -24.45 12/31/24 - -70.51 Current Ratio 06/30/25 - - 03/31/25 - 2.78 12/31/24 - 3.53 Quick Ratio 06/30/25 - - 03/31/25 - 2.78 12/31/24 - 3.53 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Book Value 06/30/25 - - 03/31/25 - 0.72 12/31/24 - 0.88 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00

Powered by Zacks Investment Research ©